Clinical Trials Browser

INDUSTRY × Isotretinoin × Clear all

NCT06047535 2023-09-21

Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.

Phase 4 Not yet recruiting

Neuroblastoma

NCT04909515 2022-09-01

Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.

Phase 2 Withdrawn

Neuroblastoma

NCT03291080 2021-10-19

My-CRA

Phase 1/2 Completed

20 enrolled 15 charts

Neuroblastoma

NCT01592045 2015-09-23

ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

Phase 1/2 Completed

28 enrolled 11 charts

Neuroblastoma

NCT00969722 2013-03-08

A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients

Phase 2 Terminated

Neuroblastoma